Biotech Values

[genisi]

Ok—you’re essentially talking about generic Atripla, a combination that is on its way toward becoming obsolete due to the superiority of II-containing regimens.

Dolutegravir/abacavir/lamivudine was indeed superior to Atripla in phase III, but Stribild was non-inferior. Again, I think that generic Atripla (once available) can be required by payors ahead of newer regimens if there are no compelling data to convince otherwise.